Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers. NPJ Precision Oncology, 2021 by Reaction Biology | Jul 6, 2023
Establishment of a methodological platform for the exploration of MCL1 inhibitors by Reaction Biology | Jul 6, 2023
A systems biology approach combining ProLiFiler™ and Cancer Data Miner for an enhanced preclinical characterization of the Wee1 inhibitor adavosertib by Reaction Biology | Jul 6, 2023